Appeals Court Rejects GlaxoSmithKline's Bid for Augmentin Patent

Law360, New York (November 22, 2003, 12:00 AM EST) -- The U.S. Court of Appeals for the Federal Circuit on Friday rejected GlaxoSmithKline Plc's bid to salvage patent protection for its antibiotic Augmentin.

The appeals court ruled that a lower court had been correct when it decided early last year that the company's patents were invalid.

The court ruled in favor of generic drug makers Geneva Pharmaceuticals, Teva Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd. .

Geneva, the generics unit of Swiss-based Novartis AG , was the first to launch a generic version of Augmentin in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.